Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors

Health Physics

Volumn 106, Issue 1, 2014, Pages 21-38

  Chua, Hui Lin ^a   Plett, P Artur ^a   Sampson, Carol H ^a   Katz, Barry P ^a   Carnathan, Gilbert W ^c   Macvittie, Thomas J ^b   Lenden, Keith ^c   Orschell, Christie M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MAXYGEN INC   (United States)

Author keywords

blood; bone marrow; mice; radiation damage

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL DERIVATIVE; MAXY G34; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ACUTE RADIATION SYNDROME; ANIMAL; ARTICLE; BLOOD; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CYCLE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOPOIESIS; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION EXPOSURE; SURVIVAL; SURVIVOR; TIME;

ACUTE RADIATION SYNDROME; ANIMALS; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL CYCLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; MALE; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 84889592800     PISSN: 00179078     EISSN: 15385159     Source Type: Journal    
DOI: 10.1097/HP.0b013e3182a4df10     Document Type: Article

References (61)

1. Abuchowski A, Kazo GM, Verhoest CR Jr, Van Es T, Kafkewitz D, Nucci ML, Viau AT, Davis FF. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7: 175-186; 1984
2. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193-197; 2000
3. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, longlasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195-202; 2001
4. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96: 80-85; 2000
5. Botnick LE, Hannon EC, Hellman S. A long lasting proliferative defect in the hematopoietic stem cell compartment following cytotoxic agents. Int J Radiat Oncol Biol Phys 5: 1621-1625; 1979
6. Bradfute SB, Graubert TA, Goodell MA. Roles of Sca-1 in hematopoietic stem/progenitor cell function. Exp Hematol 33: 836-843; 2005
7. Chua HL, Plett PA, Sampson CH, Joshi M, Tabbey R, Katz BP, MacVittie TJ, Orschell CM. Long-term hematopoietic stem cell damage in a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 103: 356-366; 2012
8. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164-170; 1991
9. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. The hematologist and radiation casualties. Hematol 473-496; 2003
10. Demetri GD. Hematopoietic growth factors: Current knowledge, future prospects. Current Problems in Cancer 16: 177-259; 1992
11. Drouet M, Delaunay C, Grenier N, Garrigou P, Mayol JF, Herodin F. Cytokines in combination to treat radiationinduced myelosuppresssion: Evaluation of SCF + glycosylated EPO + PEGylated G-CSF as an emergency treatment in highly irradiated monkeys. Haematologica 93: 465-466; 2008
12. Farese A, Cohen M, Stead R, Jackson III W, MacVittie T. PEG-filgrastim, administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose, radiation-induced meylosuppression in rhesus macaques. Radiat Res 178: 403-413; 2012
13. Farese AM, Cohen MV, Katz BP, Smith CP, Gibbs A, Cohen DM, MacVittie TJ. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res 179: 89-100; 2013
14. Farese A, Cohen M, Stead R, Jackson III W, MacVittie T. Pegfilgrastim, administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose, radiation-induced meylosuppression in rhesus macaques. Radiat Res. 179: 403-413; 2012
15. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.J Clin Invest 97: 2145-2151; 1996
16. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K,Welte K, Souza L. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine 318: 1414-1422; 1988
17. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 109: 93-99; 2007
18. Gothot A, van der Loo J, Clapp W, Srour E. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34+ cells in non-obese diabetic/severe combined immune-deficient mice. Blood 92: 2641-2649; 1998
19. Habibian HK, Peters SO, Hsieh CC, Wuu J, Vergilis K, Grimaldi CI, Reilly J, Carlson JE, Frimberger AE, Stewart FM, Quesenberry PJ. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Experimental Medicine 188: 393-398; 1998
20. Hellman S, Botnick LE. Stem cell depletion: An explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 2: 181-184; 1977
21. Herodin F, Grenier N, Drouet M. Revisiting therapeutic strategies in radiation casualties. Exp Hematol 35: 28-33; 2007
22. Hirayama Y, Sakamaki S, Matsunaga T, Kuroda H, Kusakabe T, Akiyama T, Kato J, Kogawa K, Koyama R, Nagai T, Ohta H, Niitsu Y. Granulocyte-colony stimulating factor enhances the expression of transforming growth factor-beta mRNA in CD4-positive peripheral blood lymphocytes in the donors for allogeneic peripheral blood stem cell transplantation. Am J Hematol 69: 138-140; 2002
23. Holmes C, Stanford WL. Concise review: Stem cell antigen-1: Expression, function, and enigma. Stem Cells 25: 1339-1347; 2007
24. Ito CY, Li CY, Bernstein A, Dick JE, Stanford WL. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 101: 517-523; 2003
25. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263: 15064-15070; 1988
26. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91: 661-672; 1997
27. Ladd A, Pyatt R, Gothot A, Rice S, McMahel J, Traycoff C, Srour E. Orderly process of sequential cytokine stimulation is required for activation and maximal proliferation of primitive human bone marrow CD34+ hematopoietic progenitor cells residing in G0. Blood 90: 658-668; 1997
28. Long KK, Montano M, Pavlath GK. Sca-1 is negatively regulated by TGF-beta1 in myogenic cells. FASEB J 25: 1156-1165; 2011
29. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clinical Cancer Research 7: 2085-2090; 2001
30. MacVittie TJ, Farese AM, Jackson W 3rd. Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: The effect of supportive care plus administration of G-CSF. Health Phys 89: 546-555; 2005
31. MacVittie TJ, Monroy RL, Patchen ML, Souza LM. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. International J Radiat Biol 57: 723-736; 1990
32. Mauch P, Rosenblatt M, Hellman S. Permanent loss in stem cell self renewal capacity following stress to the marrow. Blood 72: 1193-1196; 1988
33. Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res 63: 5414-5419; 2003
34. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27: 1724-1734; 1999
35. Moroni M, Ngudiankama BF, Christensen C, Olsen CH, Owens R, Lombardini ED, Holt RK, Whitnall MH. The Gottingen minipig is a model of the hematopoietic actue radiation syndrome: G-CSF stimulates hematopoiesis and enhances survival from lethal total-body gamma-irradiation. International J Radiat Oncol Biol Physics 86: 986-992; 2013
36. Neta R, Oppenheim JJ. Cytokines in therapy of radiation injury. Blood 72: 1093-1095; 1988
37. Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocytemacrophage colony-stimulating factor. J Immunol 140: 108-111; 1988
38. Nilsson SK, Dooner MS, Quesenberry PJ. Synchronized cellcycle induction of engrafting long-term repopulating stem cells. Blood 90: 4646-4650; 1997
39. Orschell-Traycoff CM, Hiatt K, Dagher RN, Rice S, Yoder MC, Srour EF. Homing and engraftment potential of Sca-1(+)lin(-) ells fractionated on the basis of adhesion molecule expression and position in cell cycle. Blood 96: 1380-1387; 2000
40. Patchen ML. Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: Preclinical experience in animals models. European J Cancer 31: S17-S21; 1995
41. Patchen ML, Fischer R, MacVittie TJ. Effects of combined administration of interleukin-6 and granulocyte colonystimulating factor on recovery from radiation-induced hemopoietic aplasia. Experimental Hematol 21: 338-344; 1993
42. Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Seminars Oncol 21: 26-32; 1994
43. Patchen ML, MacVittie TJ, Solberg BD, Souza LM. Survival enhancement and hemopoietic regeneration following radiation exposure: Therapeutic approach using glucan and granulocyte colony-stimulating factor. Experimental Hematol 18: 1042-1048; 1990
44. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. International J Radiat Oncol Biol Phys 22: 773-779; 1992
45. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 87: 30-37; 1996
46. Plett PA, Sampson CH, Chua HL, Joshi M, Booth C, Gough A, Johnson CS, Katz BP, Farese AM, Parker J, MacVittie TJ, Orschell CM. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 103: 343-355; 2012
47. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui CH. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101: 3862-3867; 2003
48. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107: 4628-4635; 2006
49. Scholz M, Engel C, Apt D, Sankar SL, Goldstein E, Loeffler M. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. Cell Prolif 42: 823-837; 2009
50. Schuening FG, Appelbaum FR, Deeg HJ, Sullivan-Pepe M, Graham TC, Hackman R, Zsebo KM, Storb R. Effects of recombinant canine stem cell factor, a C-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 81: 20-26; 1993
51. Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR, Hackman R, Souza LM. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 74: 1308-1313; 1989
52. Schuening FG, Storb R, Goehle S, Nash R, Graham TC, Appelbaum FR, Hackman R, Sandmaier BM, Urdal DL. Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 17: 889-894; 1989
53. Schwartzberg LS, Sankar SL, Apt D, Goldstein E, Vetticaden SJ, Chitour K, Gilfoyle D, Kim S, Keilholz U, Possinger K. An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting PEGylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN). J Clinical Oncol 27: E14500; 2009
54. Simonnet AJ, Nehme J, Vaigot P, Barroca V, Leboulch P, Tronik-Le Roux D. Phenotypic and functional changes induced in hematopoietic stem/progenitor cells after gamma-ray radiation exposure. Stem Cells 27: 1400-1409; 2009
55. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21: 1195-1204; 2003
56. Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f) actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99: 183-186; 2007
57. Uckun FM, Souza L, Waddick KG, Wick M, Song CW. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 75: 638-645; 1990
58. van Os R, Robinson S, Sheridan T, Mauch PM. Granulocytecolony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal. Stem Cells 18: 120-127; 2000
59. Verfaillie CM, Miller JS. A novel single-cell proliferation assay shows that long-term culture-initiating cell (LTC-IC) maintenance over time results from the extensive proliferation of a small fraction of LTC-IC. Blood 86: 2137-2145; 1995
60. Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107: 358-366; 2006
61. Xu S, Hoglund M, Venge P. The effect of granulocyte colonystimulating factor (G-CSF) on the degranulation of secondary granule proteins from human neutrophils in vivo may be indirect. Br J Haematol 93: 558-568; 1996 Diseases